23 Feb Sernova

Philip Toleikis, Ph.D., President and CEO
London, Ontario, Canada
(TSX-V: SVA)
Sernova is developing regenerative medicine therapeutic technologies using the Cell Pouch System, a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy and has been proven to provide a biologically compatible environment for insulin-producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown the presence of blood levels of c-peptide both during glucose tolerance tests as well as under fasting conditions.
www.sernova.com